SUMMARY

• LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.¹
• The recommended dosage of LAZCLUZE is 240 mg orally (PO) once daily (QD), with or without food, given in combination with RYBREVANT. Administer LAZCLUZE any time prior to RYBREVANT when given on the same day. Do not cut, crush, or chew tablets.¹
• If a patient misses a dose of LAZCLUZE within 12 hours, instruct the patient to take the missed dose. If more than 12 hours have passed since the dose was to be given, instruct the patient to take the next dose at its scheduled time.¹
• Please refer to full Prescribing Information for complete dosage and administration information.¹

PRODUCT LABELING

• LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.
• RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 16 August 2024.